Nanocarrier possibilities for functional targeting of bioactive peptides and proteins: State-of-the-art

Journal of Drug Targeting

Volumn 20, Issue 2, 2012, Pages 114-141

  Moutinho, Carla G ^a,b   Matos, Carla M ^a   Teixeira, José A ^b   Balcão, Victor M ^a,b  

^a UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

Author keywords

Biopharmaceutical applications; Dairy bioactive proteins and peptides; Functional targeting; Multiple emulsions; Nanoparticles

Indexed keywords

ALPHA CASEIN; ALPHA LACTALBUMIN; ALPHA LACTALBUMIN F51-53; ALPHA LACTORPHIN; ANTIHYPERTENSIVE AGENT; BETA CASEIN; BETA CASEIN F191-193; BETA CASEIN F54-59; BETA CASOMORPHINE; BETA LACTOGLOBULIN; BETA LACTORPHIN; CASEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOPROTEIN; ISOLEUCYLPROLYLPROLINE; LACTOFERRICIN; LACTOFERRIN; LACTOFERROXIN; LACTOPEROXIDASE; LIPOSOME; MILK PROTEIN; MORPHICEPTIN; NANOCARRIER; OPIATE PEPTIDE; PHENYLALANYLPHENYLALANYLVALYLALANYLPROLYLPHENYLALANYLPROLYLGLUTAMYLVALYLPHENYLALANYLGLYCYLLYSINE; POLYLACTIC ACID; PROTEIN HYDROLYSATE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; VALYLPROLYLPROLINE; WHEY PROTEIN HYDROLYSATE;

ANTIMICROBIAL ACTIVITY; CARDIOVASCULAR SYSTEM; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; FERMENTATION; FOOD PROCESSING; HUMAN; HYDROLYSIS; IMMUNOMODULATION; MICELLE; MICROEMULSION; NANOEMULSION; NANOTECHNOLOGY; NERVOUS SYSTEM; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN INTAKE; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; DAIRY PRODUCTS; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EMULSIONS; HUMANS; LIPOSOMES; MICELLES; NANOPARTICLES; PEPTIDES; PROTEINS;

EID: 84855675684     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2011.628397     Document Type: Review

References (343)

1. Addeo F, Chianese L, Salzano A, Sacchi F, Cappuccio U, Ferranti P, Malorni A. (1992). Characterization of the 12 % trichloroacetic acid-insoluble oligopeptides of Parmigiano-Reggiano cheese. J Dairy Res 59, 401-411.
2. Allémann E, Leroux J, Gurny R. (1998). Polymeric nano-and microparticles for the oral delivery of peptides and peptidomimetics. Adv Drug Deliv Rev, 34, 171-189. (Pubitemid 28535111)
3. Almeida AJ, Runge S, Muller RH. (1997). Peptide loaded solid lipid nanoparticles (SLN): Influence of production parameters. Int J Pharm 149, 255-265. (Pubitemid 27193412)
4. Amacker M, Engler O, Kammer AR, Vadrucci S, Oberholzer D, Cerny A, Zurbriggen R. (2005). Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int Immunol, 17, 695-704. (Pubitemid 41417967)
5. Andresen TL, Jensen SS, Joørgensen K. (2005). Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release. Prog Lipid Res, 44, 68-97. (Pubitemid 40313220)
6. Anjos JL, Santiago PS, Tabak M, Alonso A. (2011). On the interaction of bovine serum albumin with ionic surfactants: Temperature induced EPR changes of a maleimide nitroxide reflect local protein dynamics and probe solvent accessibility. Colloids Surf B Biointerfaces, 88, 463-470.
7. Antila P, Paakkari I, Järvinen A, Mattila MJ, Laukkanen M, Pihlanto-Leppälä A, Mäntsälä P, Hellman J. (1991). Opioid peptides derived from in vitro proteolysis of bovine whey proteins. Int Dairy J 1, 215-229.
8. Anton N, Benoit JP, Saulnier P. (2008). Design and production of nanoparticles formulated from nano-emulsion templates-a review. J Control Release, 128, 185-199.
9. Arifin DR, Palmer AF. (2003). Determination of size distribution and encapsulation efficiency of liposome-encapsulated hemoglobin blood substitutes using asymmetric flow field-flow fractionation coupled with multi-angle static light scattering. Biotechnol Prog, 19, 1798-1811. (Pubitemid 37529218)
10. Ariyoshi, Y. (1993). Angiotensin-converting enzyme inhibitors derived from food proteins. Trends in Food Sci Technol 4, 139-144.
11. Arnold RR, Russell JE, Champion WJ, Brewer M, Gauthier JJ. (1982). Bactericidal activity of human lactoferrin: Differentiation from the stasis of iron deprivation. Infect Immun, 35, 792-799.
12. Asai T, Oku N. (2005). Liposomalized oligopeptides in cancer therapy. Meth Enzymol, 391, 163-176. (Pubitemid 40254034)
13. Ashar MN, Chand R. (2004). Fermented milk containing ACEinhibitory peptides reduces blood pressure in middle aged hypertensive subjects. Milchwissenschaft 59, 363-366. (Pubitemid 38946885)
14. Atanasova J, Ivanova I. (2010). Antibacterial peptides from goat and sheep milk proteins. Biotechnol & Biotechnol Eq 24, 1799-1803.
15. Ayame H, Morimoto N, Akiyoshi K. (2008). Self-assembled cationic nanogels for intracellular protein delivery. Bioconjug Chem, 19, 882-890. (Pubitemid 351614544)
16. Bader RA, Silvers AL, Zhang N. (2011). Polysialic acid-based micelles for encapsulation of hydrophobic drugs. Biomacromolecules, 12, 314-320.
17. Badiee A, Jaafari MR, Khamesipour A. (2007). Leishmania major: Immune response in BALB/c mice immunized with stressinducible protein 1 encapsulated in liposomes. Exp Parasitol, 115, 127-134. (Pubitemid 44820050)
18. Badiee A, Jaafari MR, Khamesipour A, Samiei A, Soroush D, Kheiri MT, Barkhordari F, McMaster WR, Mahboudi F. (2009). The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63). Exp Parasitol, 121, 362-369.
19. Barbe CJ, Kong L, Finnie KS, Calleja S, Hanna JV, Drabarek E, Cassidy DT, Blackford MG. (2008). Sol-gel matrices for controlled release: From macro to nano using emulsion polymerization. J Sol-Gel Sci Technol 46, 393-409.
20. Basomba A, Tabar AI, de Rojas DH, García BE, Alamar R, Olaguíbel JM, del Prado JM, Martín S, Rico P. (2002). Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: A randomized, double-blind, placebo-controlled trial in asthmatic patients. J Allergy Clin Immunol, 109, 943-948. (Pubitemid 34634303)
21. Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K, Tomita M. (1992). Identification of the bactericidal domain of lactoferrin. Biochim Biophys Acta, 1121, 130-136.
22. Berrocal R, Chanton S, Juillerat MA, Pavillard B, Scherz JC, Jost R. (1989). Tryptic phosphopeptides from whole casein. II. Physicochemical properties related to the solubilization of calcium. J Dairy Res, 56, 335-341.
23. Bernkop-Schnürch A, Schmitz T. (2007). Presystemic metabolism of orally administered peptide drugs and strategies to overcome it. Curr Drug Metab, 8, 509-517. (Pubitemid 47603415)
24. Bernkop-Schnürch A. (1998). The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J Control Release, 52, 1-16. (Pubitemid 28123168)
25. Berthou J, Migliore-Samour D, Lifchitz A, Delettré J, Floc'h F, Jollès P. (1987). Immunostimulating properties and three-dimensional structure of two tripeptides from human and cow caseins. FEBS Lett, 218, 55-58. (Pubitemid 17090936)
26. Bhaskar S, Tian F, Stoeger T, Kreyling W, de la Fuente JM, Grazú V, Borm P, Estrada G, Ntziachristos V, Razansky D. (2010). Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: Perspectives on tracking and neuroimaging. Part Fibre Toxicol, 7, 3.
27. Bhave S, Sewak P, Saxena J. (1989). Nanoparticles: New colloidal drug delivery system. Eastern Pharmacology 32, 17-20.
28. Bi R, Zhang N. (2007). Liposomes as a carrier for pulmonary delivery of peptides and proteins. J Biomed Nanotech 3, 332-341. (Pubitemid 351877136)
29. Bi R, Shao W, Wang Q, Zhang N. (2008). Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J Drug Target, 16, 639-648.
30. Bio-Path Holdings, Inc., 2011). First Cohort Successfully Completed in Bio-Path Holding's Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia.
31. Birnbaumer G, Küpcü S, Jungreuthmayer C, Richter L, Vorauer-Uhl K, Wagner A, Valenta C, Sleytr U, Ertl P. (2011). Rapid liposome quality assessment using a lab-on-a-chip. Lab Chip, 11, 2753-2762.
32. Bjerregaard S, Wulf-Andersen L, Stephens RW, Roøge Lund L, Vermehren C, Söderberg I, Frokjaer S. (2001). Sustained elevated plasma aprotinin concentration in mice following intraperitoneal injections of w/o emulsions incorporating aprotinin. J Control Release, 71, 87-98. (Pubitemid 32195443)
33. Boman HG. (2003). Antibacterial peptides: Basic facts and emerging concepts. J Intern Med, 254, 197-215. (Pubitemid 37070221)
34. Borm PJ, Kreyling W. (2004). Toxicological hazards of inhaled nanoparticles-potential implications for drug delivery. J Nanosci Nanotechnol, 4, 521-531. (Pubitemid 39387404)
35. Branco MC, Schneider JP. (2009). Self-assembling materials for therapeutic delivery. Acta Biomater, 5, 817-831.
36. Brantl V, Teschemacher H, Henschen A, Lottspeich F. (1979). Novel opioid peptides derived from casein (?-casomorphins). I. Isolation from bovine casein peptone. Hoppe-Seyler's Z Physiol Chem, 360, 1211-1216. (Pubitemid 10231176)
37. Brgles M, Mirosavljevic K, Noethig-Laslo V, Frkanec R, Tomasic J. (2007). Spin-labelling study of interactions of ovalbumin with multilamellar liposomes and specific anti-ovalbumin antibodies. Int J Biol Macromol, 40, 312-318. (Pubitemid 46240289)
38. Caboche S, Leclère V, Pupin M, Kucherov G, Jacques P. (2010). Diversity of monomers in nonribosomal peptides: Towards the prediction of origin and biological activity. J Bacteriol, 192, 5143-5150.
39. Carsten R, Ulrike S, Aurora O. (2004). Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo. Pharm Res, 21, 1662-1669.
40. Carstens MG, de Jong PH, van Nostrum CF, Kemmink J, Verrijk R, de Leede LG, Crommelin DJ, Hennink WE. (2008). The effect of core composition in biodegradable oligomeric micelles as taxane formulations. Eur J Pharm Biopharm, 68, 596-606. (Pubitemid 351318214)
41. Centis Valerei, Proulx Pierre, Vermette Patrick. (2011). PEGylated liposomes encapsulating human hemoglobin enhance oxygen transfer and cell proliferation while decreasing cell hypoxia in fibrin. Biochem Eng J, 55, 162-16.
42. Cevc G, Schätzlein A, Blume G. (1995). Transdermal drug carriers: Basic properties, optimization and transfer efficiency in the case of epicutaneously applied peptides. J Control Rel 36, 3-16.
43. Chabance B, Jollès P, Izquierdo C, Mazoyer E, Francoual C, Drouet L, Fiat AM. (1995). Characterization of an antithrombotic peptide from ?-casein in newborn plasma after milk ingestion. Br J Nutr, 73, 583-590.
44. Chaix C, Pacard E, Elaissari A, Hilaire JF, Pichot C. (2003). Surface functionalization of oil-in-water nanoemulsion with a reactive copolymer: Colloidal characterization and peptide immobilization. Coll Surf B Bioint, 29, 39-52. (Pubitemid 36411812)
45. Chan VS. (2006). Nanomedicine: An unresolved regulatory issue. Regul Toxicol Pharmacol, 46, 218-224. (Pubitemid 44692901)
46. Chang KJ, Su YF, Brent DA, Chang JK. (1985). Isolation of a specific mu-opiate receptor peptide, morphiceptin, from an enzymatic digest of milk proteins. J Biol Chem, 260, 9706-9712. (Pubitemid 15013028)
47. Chen H, Tang L, Qin Y, Yin Y, Tang J, Tang W, Sun X, Zhang Z, Liu J, He Q. (2010). Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. Eur J Pharm Sci, 40, 94-102.
48. Chen M, Deng Q, Li XR, Liu Y. (2007). [The hypocalcemia effect of salmon calcitonin ultra-flexible liposomes after intranasal administration in rats]. Yao Xue Xue Bao, 42, 681-686.
49. Chen M, Li XR, Zhou YX, Yang KW, Chen XW, Deng Q, Liu Y, Ren LJ. (2009). Improved absorption of salmon calcitonin by ultraflexible liposomes through intranasal delivery. Peptides, 30, 1288-1295.
50. Chen W, Yan W, Huang L. (2008). A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother, 57, 517-530. (Pubitemid 351170535)
51. Chen W, Jin MJ, Gao ZG, Wang LP, Piao HF. (2011). [Preparation and in vitro evaluation of pH-sensitive TAT peptide conjugated micelles]. Yao Xue Xue Bao, 46, 599-604.
52. Chen ZY, Peng C, Jiao R, Wong YM, Yang N, Huang Y. (2009). Antihypertensive nutraceuticals and functional foods. J Agric Food Chem, 57, 4485-4499.
53. Cheng MB, Wang JC, Li YH, Liu XY, Zhang X, Chen DW, Zhou SF, Zhang Q. (2008). Characterization of water-in-oil microemulsion for oral delivery of earthworm fibrinolytic enzyme. J Control Release, 129, 41-48.
54. Cheng W, Lim LY. (2009). Synthesis, characterization and in vivo activity of salmon calcitonin coconjugated with lipid and polyethylene glycol. J Pharm Sci, 98, 1438-1451.
55. Cheng W, Lim LY. (2010). Design, synthesis, characterization and in-vivo activity of a novel salmon calcitonin conjugate containing a novel PEG-lipid moiety. J Pharm Pharmacol, 62, 296-304.
56. Cheung HS, Wang FL, Ondetti MA, Sabo EF, Cushman DW. (1980). Binding of peptide substrates and inhibitors of angiotensinconverting enzyme. Importance of the COOH-terminal dipeptide sequence. J Biol Chem, 255, 401-407.
57. Chiang HS, Huang YC, Yeh HY, Yeh SY, Huang YY. (2009). The Drug release from liposomal carrier within the chitosan matrix. Biomed Eng Applic Bas 21, 107-114.
58. Chiba H Yoshikawa M (1986). Biologically functional peptides from food proteins: New opioid peptides from milk proteins. Protein Tailoring for Food and Medical Uses, (eds). R.E. Feeney and J.R. Whitaker, New York, Marcel Dekker pp. 123-153.
59. Cilek A, Celebi N, Tirnaksiz F. (2006). Lecithin-based microemulsion of a peptide for oral administration: Preparation, characterization, and physical stability of the formulation. Drug Deliv, 13, 19-24. (Pubitemid 43087616)
60. Cohen JA, Beaudette TT, Tseng WW, Bachelder EM, Mende I, Engleman EG, Fréchet JM. (2009). T-cell activation by antigenloaded pH-sensitive hydrogel particles in vivo: The effect of particle size. Bioconjug Chem, 20, 111-119.
61. Cortês EV, Felipe MDD, Roberto IC, Pessoa A, Vitolo M. (2001). Extraction by reversed micelles of the intracellular enzyme xylose reductase. App Biochem Biotech 91, 753-759. (Pubitemid 32451734)
62. Croy SR, Kwon GS. (2006). Polymeric micelles for drug delivery. Curr Pharm Des, 12, 4669-4684. (Pubitemid 44835136)
63. Dai C, Wang B, Zhao H, Li B. (2005). Factors affecting protein release from microcapsule prepared by liposome in alginate. Colloids Surf B Biointerfaces, 42, 253-258. (Pubitemid 40693983)
64. Dai C, Wang B, Zhao H, Li B, Wang J. (2006). Preparation and characterization of liposomes-in-alginate (LIA) for protein delivery system. Colloids Surf B Biointerfaces, 47, 205-210. (Pubitemid 43212886)
65. Daniel H, Vohwinkel M, Rehner G. (1990). Effect of casein and ?-casomorphins on gastrointestinal motility in rats. J Nutr, 120, 252-257. (Pubitemid 20130741)
66. Deng W, Li J, Yao P, He F, Huang C. (2010). Green preparation process, characterization and antitumor effects of doxorubicin-BSAdextran nanoparticles. Macromol Biosci, 10, 1224-1234.
67. Dionysius DA, Milne JM. (1997). Antibacterial peptides of bovine lactoferrin: Purification and characterization. J Dairy Sci, 80, 667-674. (Pubitemid 127446978)
68. Doktorovovà S, Morsy T, Balcão VM, Souto EB. (2008). The role of lipids in drug absorption through the GIT. Revista da Faculdade de Ciências da Saúde da Universidade Fernando Pessoa 5, 192-199.
69. Dong ZH, Chang SX, Kai JH. (2003). The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 24, 1781-1785.
70. Doussin S, Birlirakis N, Georgin D, Taran F, Berthault P. (2006). Novel zwitterionic reverse micelles for encapsulation of proteins in lowviscosity media. Chemistry, 12, 4170-4175. (Pubitemid 43772132)
71. Duncan MR, Lee JM, Warchol MP. (1995). Infl uence of surfactants upon protein/peptide adsorption to glass and polypropylene. Int J Pharm, 120, 179-188.
72. Edwards KA, Baeumner AJ. (2006). Analysis of liposomes. Talanta, 68, 1432-1441. (Pubitemid 43144497)
73. Ellison RT 3rd, Giehl TJ, LaForce FM. (1988). Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infect Immun, 56, 2774-2781. (Pubitemid 18259927)
74. Ellison RT 3rd, Giehl TJ. (1991). Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest, 88, 1080-1091.
75. Fiat AM, Levy-Toledano S, Caen JP, Jollès P. (1989). Biologically active peptides of casein and lactotransferrin implicated in platelet function. J Dairy Res, 56, 351-355.
76. FitzGerald RJ, Meisel H. (2000). Milk protein-derived peptide inhibitors of angiotensin-I-converting enzyme. Br J Nutr, 84 Suppl 1, S33-S37. (Pubitemid 32106827)
77. FitzGerald RJ, Murray BA, Walsh DJ. (2004). Hypotensive peptides from milk proteins. J Nutr, 134, 980S-988S. (Pubitemid 38456275)
78. Fricker G, Kromp T, Wendel A, Blume A, Zirkel J, Rebmann H, Setzer C, Quinkert RO, Martin F, Müller-Goymann C. (2010). Phospholipids and lipid-based formulations in oral drug delivery. Pharm Res, 27, 1469-1486.
79. Frkanec R, Travas D, Krstanovic M, Spoljar BH, Ljevakovic D, Vranesic B, Frkanec L, Tomasic J. (2003a). Entrapment of peptidoglycans and adamantyltripeptides into liposomes: An HPLC assay for determination of encapsulation efficiency. J Liposome Res, 13, 279-294. (Pubitemid 37486246)
80. Frkanec R, Noethig-Laslo V, Vranesic B, Mirosavljevic K, Tomasic J. (2003b). A spin labelling study of immunomodulating peptidoglycan monomer and adamantyltripeptides entrapped into liposomes. Biochim Biophys Acta, 1611, 187-196. (Pubitemid 36351447)
81. Fuentes MG, Torres D, Alonso MJ. (2002). Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Coll Surf B Bioint, 27, 159-168.
82. Fujita H, Yoshikawa M. (1999). LKPNM: A prodrug-type ACE-inhibitory peptide derived from fish protein. Immunopharmacology, 44, 123-127.
83. Gagnaire V, Pierre A, Molle D, Leonil J. (1996). Phosphopeptides interacting with colloidal calcium phosphate isolated by tryptic hydrolysis of bovine casein micelles. J Dairy Res, 63, 405-422. (Pubitemid 126599346)
84. Galovic Rengel R, Barisic K, Pavelic Z, Zanic Grubisic T, Cepelak I, Filipovic-Grcic J. (2002). High efficiency entrapment of superoxide dismutase into mucoadhesive chitosan-coated liposomes. Eur J Pharm Sci, 15, 441-448.
85. Garcia-Fuentes M, Prego C, Torres D, Alonso MJ. (2005a). A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly (ethylene glycol) as carriers for oral calcitonin delivery. Eur J Pharm Sci, 25, 133-143. (Pubitemid 40602203)
86. Garcia-Fuentes M, Torres D, Alonso MJ. (2005b). New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharm, 296, 122-132. (Pubitemid 40693381)
87. Garg A, Tisdale AW, Haidari E, Kokkoli E. (2009). Targeting colon cancer cells using PEGylated liposomes modified with a fibronectinmimetic peptide. Int J Pharm, 366, 201-210.
88. Gaspar MM, Boerman OC, Laverman P, Corvo ML, Storm G, Cruz ME. (2007). Enzymosomes with surface-exposed superoxide dismutase: In vivo behaviour and therapeutic activity in a model of adjuvant arthritis. J Control Release, 117, 186-195. (Pubitemid 46172500)
89. Gaubert S, Bayer E, Delord B, Roux D, Amédée J, Auriault C, Guillén C, McInnes IB, Vaughan D, Speekenbrink ABJ, Brock JH. (2000). The effects of local administration of lactoferrin on inflammation in murine autoimmune and infectious arthritis. Arthritis Rheum, 43, 2073-2080.
90. Ge W, Li Y, Li ZS, Zhang SH, Sun YJ, Hu PZ, Wang XM, Huang Y, Si SY, Zhang XM, Sui YF. (2009). The antitumor immune responses induced by nanoemulsion-encapsulated MAGE1-HSP70/SEA complex protein vaccine following peroral administration route. Cancer Immunol Immunother, 58, 201-208.
91. Gein SV, Baeva TA. (2011). Endogenous opioid peptides in regulation of innate immunity cell functions. Biochemistry Mosc, 76, 309-319.
92. Gerhardt NI, Dungan SR. (2002). Time-dependent solubilization of IgG in AOT-brine-isooctane microemulsions: Role of cluster formation. Biotechnol Bioeng, 78, 60-72. (Pubitemid 34716212)
93. Gobetti M, Minervini F Rizzello CG. (2004). Angiotensin I-convertingenzyme-inhibitory and antimicrobial bioactive peptides. Int J Dairy Technol, 57, 173-188.
94. Gomez-Ruiz JÀ,, Ramos M, Recio I. (2002). Angiotensin-converting enzyme-inhibitory peptides in Manchego cheeses manufactured with different starter cultures. Int Dairy J 12, 697-706.
95. Gong J, Huo M, Zhou J, Zhang Y, Peng X, Yu D, Zhang H, Li J. (2009). Synthesis, characterization, drug-loading capacity and safety of novel octyl modified serum albumin micelles. Int J Pharm, 376, 161-168.
96. Goyal P, Goyal K, Vijaya Kumar SG, Singh A, Katare OP, Mishra DN. (2005). Liposomal drug delivery systems-clinical applications. Acta Pharm, 55, 1-25. (Pubitemid 40562616)
97. Grafa A, Jackb KS, Whittakerb AK, Hooka SM, Radesa T. (2008). Protein delivery using nanoparticles based on microemulsions with different structure-types. Eur J Pharm Sci 33, 434-444.
98. Gualbert J, Shahgaldian P, Coleman AW. (2003). Interactions of amphiphilic calix[4]arene-based Solid Lipid Nanoparticles with bovine serum albumin. Int J Pharm, 257, 69-73. (Pubitemid 36507033)
99. Guo XD, Tandiono F, Wiradharma N, Khor D, Tan CG, Khan M, Qian Y, Yang YY. (2008). Cationic micelles self-assembled from cholesterol-conjugated oligopeptides as an efficient gene delivery vector. Biomaterials, 29, 4838-4846.
100. Hajos F, Stark B, Hensler S, Prassl R, Mosgoeller W. (2008). Inhalable liposomal formulation for vasoactive intestinal peptide. Int J Pharm, 357, 286-294.
101. Hamdy S, Haddadi A, Shayeganpour A, Alshamsan A, Montazeri Aliabadi H, Lavasanifar A. (2011). The immunosuppressive activity of polymeric micellar formulation of cyclosporine A: In vitro and in vivo studies. AAPS J, 13, 159-168.
102. Han JY, Tan TY, Loo JC. (2011). Utilizing inverse micelles to synthesize calcium phosphate nanoparticles as nano-carriers. J Nanopart Res 13, 3441-3454.
103. Harada A, Kataoka K. (1999). Chain length recognition: Coreshell supramolecular assembly from oppositely charged block copolymers. Science, 283, 65-67. (Pubitemid 29044846)
104. Harada A, Togawa H, Kataoka K. (2001). Physicochemical properties and nuclease resistance of antisense-oligodeoxynucleotides entrapped in the core of polyion complex micelles composed of poly (ethylene glycol)-poly (L-lysine) block copolymers. Eur J Pharm Sci, 13, 35-42. (Pubitemid 32259538)
105. Hazlett L, Wu M. (2011). Defensins in innate immunity. Cell Tissue Res, 343, 175-188.
106. Herbig ME, Weller K, Krauss U, Beck-Sickinger AG, Merkle HP, Zerbe O. (2005a). Membrane surface-associated helices promote lipid interactions and cellular uptake of human calcitonin-derived cell penetrating peptides. Biophys J, 89, 4056-4066. (Pubitemid 41725626)
107. Herbig ME, Fromm U, Leuenberger J, Krauss U, Beck-Sickinger AG, Merkle HP. (2005b). Bilayer interaction and localization of cell penetrating peptides with model membranes: A comparative study of a human calcitonin (hCT)-derived peptide with pVEC and pAntp (43-58). Biochim Biophys Acta, 1712, 197-211. (Pubitemid 40799305)
108. Hill RT, Shear JB. (2006). Enzyme-nanoparticle functionalization of three-dimensional protein scaffolds. Anal Chem, 78, 7022-7026. (Pubitemid 44522557)
109. Ho ML, Fu YC, Wang GJ, Chen HT, Chang JK, Tsai TH, Wang CK. (2008). Controlled release carrier of BSA made by W/O/W emulsion method containing PLGA and hydroxyapatite. J Control Release, 128, 142-148.
110. Hoek KS, Milne JM, Grieve PA, Dionysius DA, Smith R. (1997). Antibacterial activity in bovine lactoferrin-derived peptides. Antimicrob Agents Chemother, 41, 54-59. (Pubitemid 26428132)
111. Höllt V. (1983). Multiple endogenous opioid peptides. Trends Neurosci, 6, 24-26. (Pubitemid 13052378)
112. Hou DZ, Liu CK, Ping QN, Liang XH. (2007). [The entrapped efficiency of BSA liposome]. Yao Xue Xue Bao, 42, 545-549.
113. Hu FQ, Yuan H, Zhang HH, Fang M. (2002). Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharm, 239, 121-128. (Pubitemid 34615801)
114. Huang YY, Wang CH. (2006). Pulmonary delivery of insulin by liposomal carriers. J Control Release, 113, 9-14.
115. Ishikado A, Imanaka H, Kotani M, Fujita A, Mitsuishi Y, Kanemitsu T, Tamura Y, Makino T. (2004). Liposomal lactoferrin induced significant increase of the interferon-α (IFN-α) producibility in healthy volunteers. Biofactors, 21, 69-72. (Pubitemid 40921828)
116. Ishikado A, Imanaka H, Takeuchi T, Harada E, Makino T. (2005). Liposomalization of lactoferrin enhanced it's anti-inflammatory effects via oral administration. Biol Pharm Bull, 28, 1717-1721. (Pubitemid 41324139)
117. Iwanaga K, Ono S, Narioka K, Kakemi M, Morimoto K, Yamashita S, Namba Y, Oku N. (1999). Application of surface-coated liposomes for oral delivery of peptide: Effects of coating the liposome's surface on the GI transit of insulin. J Pharm Sci, 88, 248-252. (Pubitemid 29084739)
118. Iwaniak A, Minkiewicz P. (2008). Biologically active peptides derived from proteins-a review. Pol J Food Nutr Sci, 58, 289-294.
119. Jang JY, Kwon BS, Lee HE, Kim DH, Kang HK, Kang JS, Lee S, Choi GJ. (2007). Preparation of Biodegradable PLGA Nanospheres Employing a Fast Solvent Evaporation Method. J Ind Eng Chem, 13, 1043-1046.
120. Jarudilokkul S, Paulsen E, Stuckey DC. (2000). Lysozyme extraction from egg white using reverse micelles in a Graesser contactor: Mass transfer characterization. Biotechnol Bioeng, 69, 618-626. (Pubitemid 30663763)
121. Jaturanpinyo M, Harada A, Yuan X, Kataoka K. (2004). Preparation of bionanoreactor based on core-shell structured polyion complex micelles entrapping trypsin in the core cross-linked with glutaraldehyde. Bioconjug Chem, 15, 344-348. (Pubitemid 38365194)
122. Jeong JH, Kim SW, Park TG. (2003). Novel intracellular delivery system of antisense oligonucleotide by self-assembled hybrid micelles composed of DNA/PEG conjugate and cationic fusogenic peptide. Bioconjug Chem, 14, 473-479. (Pubitemid 36348672)
123. Jiang M, Wu Y, Heb Y, Nie J. (2009). Micelles formed by self-assembly of hyperbranched poly[ (amine-ester)-co-(D,L-lactide)] (HPAE-co-PLA) copolymers for protein drug delivery. Polym Int 58, 31-39.
124. Jollés P, Caen JP. (1991). Parallels between milk clotting and blood clotting: Opportunities for milk-derived products. Trends Food Sci Technol, 2, 42-43.
125. Jones M, Leroux J. (1999). Polymeric micelles -a new generation of colloidal drug carriers. Eur J Pharm Biopharm, 48, 101-111. (Pubitemid 29401986)
126. Joshi MD, Müller RH. (2009). Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm, 71, 161-172.
127. Juillerat MA, Baechler R, Berrocal R, Chanton S, Scherz JC, Jost R. (1989). Tryptic phosphopeptides from whole casein I. Preparation and analysis by fast protein liquid chromatography. J Dairy Res, 56, 603-611.
128. Kale AA, Torchilin VP. (2007). Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: The effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates. Bioconjug Chem, 18, 363-370. (Pubitemid 46493506)
129. Kakizawa Y, Harada A, Kataoka K. (2001). Glutathione-sensitive stabilization of block copolymer micelles composed of antisense DNA and thiolated poly (ethylene glycol)-block-poly (L-lysine): A potential carrier for systemic delivery of antisense DNA. Biomacromolecules, 2, 491-497. (Pubitemid 32707530)
130. Katano S, Oki T, Matsuo Y, Yoshihira K, Nara Y, Miki T, Matsui T, Matsumoto K. (2003). Antihypertensive effect of alkaline protease hydrolysate of the pearl oyster Pinctada fucata martencii and separation and identification of angiotensin-I converting enzyme inhibitory peptides. Nippon Suisan Gakkaishi, 69, 975-980. (Pubitemid 38157865)
131. Kawakamia S, Yamashitab F, Hashida M. (2000). Disposition characteristics of emulsions and incorporated drugs after systemic or local injection. Adv Drug Deliv Rev, 45, 77-88.
132. Kayser H, Meisel H. (1996). Stimulation of human peripheral blood lymphocytes by bioactive peptides derived from bovine milk proteins. FEBS Lett, 383, 18-20. (Pubitemid 26093716)
133. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. (2008). Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release, 129, 107-116.
134. Kitts DD, Weiler K. (2003). Bioactive proteins and peptides from food sources. Applications of bioprocesses used in isolation and recovery. Curr Pharm Des, 9, 1309-1323. (Pubitemid 36592139)
135. Koren E, Apte A, Sawant RR, Grunwald J, Torchilin VP. (2011). Cellpenetrating TAT peptide in drug delivery systems: Proteolytic stability requirements. Drug Deliv, 18, 377-384.
136. Korhonen H, Pihlanto A. (2003a). Food-derived bioactive peptides-opportunities for designing future foods. Curr Pharm Des, 9, 1297-1308. (Pubitemid 36592138)
137. Korhonen H, Pihlanto A. (2001b). Milk protein-derived bioactive peptides-novel opportunities for health promotion. IDF Bulletin, 363, 17-26.
138. Krawczuk S, Kostyra E, Kostyra H, Fr?czek J. (2000). Effect of nonenzymatic glycation on biological properties of morphiceptin. Pol J Food Nutr Sci, 9/50, 39-42.
139. Kreuter J. (1992). Nanoparticles-preparation and application. In Microcapsules and Nanoparticles in Medicine and Pharmacy. M. Donbrow (ed) (Boca Raton: CRC Press), pp 125-148.
140. Kshirsagar NA, Pandya SK, Kirodian GB, Sanath S. (2005). Liposomal drug delivery system from laboratory to clinic. J Postgrad Med, 51 Suppl 1, S5-15.
141. Kullberg EB, Wei Q, Capala J, Giusti V, Malmström PU, Gedda L. (2005). EGF-receptor targeted liposomes with boronated acridine: Growth inhibition of cultured glioma cells after neutron irradiation. Int J Radiat Biol, 81, 621-629. (Pubitemid 41784883)
142. Kwong B, Liu H, Irvine DJ. (2011). Induction of potent anti-tumor responses while eliminating systemic side effects via liposomeanchored combinatorial immunotherapy. Biomaterials, 32, 5134-5147.
143. Laffineur E, Genetet N, Leonil J. (1996). Immunomodulatory activity of ?-casein permeate medium fermented by lactic acid bacteria. J Dairy Sci, 79, 2112-2120. (Pubitemid 126429009)
144. Lahov E, Regelson W. (1996). Antibacterial and immunostimulating casein-derived substances from milk: Casecidin, isracidin peptides. Food Chem Toxicol, 34, 131-145. (Pubitemid 26060574)
145. Laversanne R. (2005). Amplification of Antibody Responses to Antigen Using Small Multilamellar Vesicles for Delivery System. Drug Delivery, 12, 69-74. (Pubitemid 40315360)
146. Law SL, Huang KJ, Chou HY. (2001). Preparation of desmopressincontaining liposomes for intranasal delivery. J Control Release, 70, 375-382. (Pubitemid 32155460)
147. Law SL, Huang KJ, Chou VH. (2003). Stability of desmopressin loaded in liposomes. J Liposome Res, 13, 269-277. (Pubitemid 37486245)
148. Lawrence MJ, Rees GD. (2000). Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev, 45, 89-121.
149. Lee BR, Oh KT, Baik HJ, Youn YS, Lee ES. (2010). A charge-switched nanosized polymeric carrier for protein delivery. Int J Pharm, 392, 78-82.
150. Lee ES, Na K, Bae YH. (2005a). Super pH-sensitive multifunctional polymeric micelle. Nano Lett, 5, 325-329. (Pubitemid 40308294)
151. Lee WK, Park JY, Jung S, Yang CW, Kim WU, Kim HY, Park JH, Park JS. (2005b). Preparation and characterization of biodegradable nanoparticles entrapping immunodominant peptide conjugated with PEG for oral tolerance induction. J Control Release, 105, 77-88. (Pubitemid 40805477)
152. Lee VHL, Yamamoto A. (1990). Penetration and enzymatic barriers to peptide and protein absorption. Adv Drug Deliv Rev 4, 171-207.
153. Lehrer RI. (2004). Primate defensins. Nat Rev Microbiol, 2, 727-738. (Pubitemid 39200064)
154. Li JK, Wang N, Wu XS. (1998). Gelatin nanoencapsulation of protein/peptide drugs using an emulsifier-free emulsion method. J Microencapsul, 15, 163-172. (Pubitemid 28105132)
155. Li S, Zhao B, Wang F, Wang M, Xie S, Wang S, Han C, Zhu L, Zhou W. (2010a). Yak interferon-α loaded solid lipid nanoparticles for controlled release. Res Vet Sci, 88, 148-153.
156. Li X, Zhang Y, Fan Y, Zhou Y, Wang X, Fan C, Liu Y, Zhang Q. (2011). Preparation and evaluation of novel mixed micelles as nanocarriers for intravenous delivery of propofol. Nanoscale Res Lett, 6, 275.
157. Li YZ, Sun X, Gong T, Liu J, Zuo J, Zhang ZR. (2010b). Inhalable microparticles as carriers for pulmonary delivery of thymopentinloaded solid lipid nanoparticles. Pharm Res, 27, 1977-1986.
158. Liang H, Yang Q, Deng L, Lu J, Chen J. (2011). Phospholipid-Tween 80 mixed micelles as an intravenous delivery carrier for paclitaxel. Drug Dev Ind Pharm, 37, 597-605.
159. Liang M, Davies NM, Toth I. (2008). Increasing entrapment of peptides within poly (alkyl cyanoacrylate) nanoparticles prepared from water-in-oil microemulsions by copolymerization. Int J Pharm, 362, 141-146.
160. Lin HR, Chen WJ, Ling MH. (2011). PH-sensitive Dioctadecylamine-501 polymeric micelles for delivery of insulin. J Nanosci Nanotechnol, 11, 1823-1833.
161. Liu W, He Z, Liang J, Zhu Y, Xu H, Yang X. (2008). Preparation and characterization of novel fluorescent nanocomposite particles: CdSe/ZnS core-shell quantum dots loaded solid lipid nanoparticles. J Biomed Mater Res A, 84, 1018-1025. (Pubitemid 351295012)
162. Liu XY, Song CX, Chen R, Jiang XN, Jin Y; Zou HF. (2010). Identification of Angiotensin I-Converting Enzyme Inhibitors in Peptides Mixture of Hydrolyzed Red Deer Plasma with Proteomic Approach. Chin J Chem 28, 1665-1672.
163. Lo WMY, Farnworth E, Li-Chan ECY. (2006). Angiotensin I-converting enzyme inhibitory activity of soy protein digests in a dynamic odel system simulating the upper gastrointestinal tract. J Food Sci, 71, 231-237.
164. Lochmann D, Jauk E, Zimmer A. (2004). Drug delivery of oligonucleotides by peptides. Eur J Pharm Biopharm, 58, 237-251. (Pubitemid 39037232)
165. Loukas S, Varoucha D, Zioudrou C, Streaty RA, Klee WA. (1983). Opioid activities and structures of ?-casein-derived exorphins. Biochemistry, 22, 4567-4573. (Pubitemid 13010155)
166. Lutsiak ME, Kwon GS, Samuel J. (2002). Analysis of peptide and lipopeptide content in liposomes. J Pharm Pharm Sci, 5, 279-284. (Pubitemid 37207255)
167. Mady MM, Elshemey WM. (2011). Interaction of dipalmitoyl phosphatidylcholine (DPPC) liposomes and insulin. Mol Phys 109, 1593-1598.
168. Mackay JA, Chilkoti A. (2008). Temperature sensitive peptides: Engineering hyperthermia-directed therapeutics. Int J Hyperthermia, 24, 483-495.
169. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release, 65, 271-284. (Pubitemid 30122932)
170. Maeno M, Yamamoto N, Takano T. (1996). Isolation of an antihypertensive peptide from casein hydrolysate produced by a proteinase from Lactobacillus helveticus CP790. J Dairy Sci, 79, 1316-1321. (Pubitemid 126429171)
171. Magzoub M, Kilk K, Eriksson LE, Langel U, Gräslund A. (2001). Interaction and structure induction of cell-penetrating peptides in the presence of phospholipid vesicles. Biochim Biophys Acta, 1512, 77-89. (Pubitemid 32378784)
172. Makhlof A, Fujimoto S, Tozuka Y, Takeuchi H. (2011). In vitro and in vivo evaluation of WGA-carbopol modified liposomes as carriers for oral peptide delivery. Eur J Pharm Biopharm, 77, 216-224.
173. Malhotra M, Prakash S. (2011). Targeted Drug Delivery Across Blood-Brain-Barrier Using Cell Penetrating Peptides Tagged Nanoparticles. Curr NanoSic 7, 81-93.
174. Maniar M, Loullis C, Dipali SR, Kulkarni SB, Betageri GV. (1997). Liposomal Formulation of a Cytokine Restraining Agent, (CRA)-HP 228: Encapsulation, Stability, and Release Characteristics. Drug Delivery, 4, 71-74. (Pubitemid 27276121)
175. Marcato PD, Duràn N. (2008). New aspects of nanopharmaceutical delivery systems. J Nanosci Nanotechnol, 8, 2216-2229.
176. Marcinkowska E, Superat K, Wiedlocha A. (2006). FGF-1 as a possible carrier for targeted drug delivery. Oncol Res, 16, 27-34. (Pubitemid 44195047)
177. Martins S, Sarmento B, Ferreira DC, Souto EB. (2007). Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanoparticles. Int J Nanomedicine, 2, 595-607.
178. Martínez-Gomis J, Fernàndez-Solanas A, Viñas M, Gonzàlez P, Planas ME, Sànchez S. (1999). Effects of topical application of free and liposome-encapsulated lactoferrin and lactoperoxidase on oral microbiota and dental caries in rats. Arch Oral Biol, 44, 901-906. (Pubitemid 29493202)
179. Maruyama S, Suzuki H. (1982). A peptide inhibitor of angiotensin I-convertign enzyme in the tryptic hydrolysate of casein. Agric Biol Chem 46, 1393-1394.
180. Maruyama S, Nakagomi K, Tomizuka N, Suzuki H. (1985). Angiotensin I-converting enzyme inhibitor derived from an enzymatic hydrolysate of casein. II. Isolation and bradykinin-potentiating activity on the uterus and the ileum of rats. Agric Biol Chem, 49, 1405-1409. (Pubitemid 15055043)
181. Maruyama S, Mitachi H, Tanaka H, Tomizuka N, Suzuki H. (1987a). Studies on the active site and antihypertensive activity of angiotensin I-converting enzyme inhibitors derived from casein. J Dairy Sci, 51, 1581-1586. (Pubitemid 17129021)
182. Maruyama S, Mitachi H, Awaya J, Kurono M, Tomizuka N, Suzuki H. (1987b). Angiotensin I-converting enzyme inhibitory activity of the C-terminal hexapeptide of as1-casein. Agric Biol Chem, 51, 2557-2561. (Pubitemid 18000743)
183. Masuda O, Nakamura Y, Takano T. (1996). Antihypertensive peptides are present in aorta after oral administration of sour milk containing these peptides to spontaneously hypertensive rats. J Nutr, 126, 3063-3068. (Pubitemid 27023881)
184. Matar C LeBlanc JG, Martin L, Perdigón G (2003). Biologically active peptides released in fermented milk: Role and functions. In: E.R., Farnworth. Editor. Handbook of fermented functional foods. Functional foods and nutraceuticals series. CRC Press. Florida. USA pp. 177-201.
185. McDermott AM. (2004). Defensins and other antimicrobial peptides at the ocular surface. Ocul Surf, 2, 229-247. (Pubitemid 41263861)
186. Megías C, del Mar Yust M, Pedroche J, Lquari H, Girón-Calle J, Alaiz M, Millàn F, Vioque J. (2004). Purification of an ACE inhibitory peptide after hydrolysis of sunflower (Helianthus annuus L.) protein isolates. J Agric Food Chem, 52, 1928-1932.
187. Mehnert W, Mäder K. (2001). Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev, 47, 165-196. (Pubitemid 32324113)
188. Meisel H, Frister H. (1989). Chemical characterization of bioactive peptides from in vivo digests of casein. J Dairy Res, 56, 343-349.
189. Meisel H, Behrens S, Schlimme E. (1991). Calcium-Bindungsstudien an Phosphopeptidfraktionen aus der in vitro-Proteolyse von Casein. Kieler Milchwirtschaftliche Forschungsberichte, 43, 199-212.
190. Meisel H Schlimme E (1994). Inhibitors of angiotensin converting enzyme derived from bovine casein (casokinins). b-casomorphins and related peptides: Recent developments, eds., V. Brantl and H. Teschemacher, Weinheim, New York: VCH, pp. 27-33.
191. Meisel H, Goepfert A, Gunther S. (1997). ACE-inhibitory activities in milk products. Milchwissenschaft, 52, 307-311.
192. Meisel H. (1998). Overview on milk protein-derived peptides. Int Dairy J, 8, 363-373. (Pubitemid 28504135)
193. Meisel H, FitzGerald RJ. (2003). Biofunctional peptides from milk proteins: Mineral binding and cytomodulatory effects. Curr Pharm Des, 9, 1289-1295. (Pubitemid 36592137)
194. Meisel H. (2004). Multifunctional peptides encrypted in milk proteins. Biofactors, 21, 55-61. (Pubitemid 40921826)
195. Meng M, Liu Y, Wang YB, Wang JC, Zhang H, Wang XQ, Zhang X, Lu WL, Zhang Q. (2008). Increase of the pharmacological and pharmacokinetic efficacy of negatively charged polypeptide recombinant hirudin in rats via parenteral route by association with cationic liposomes. J Control Release, 128, 113-119.
196. Mercier A, Gauthier SF, Fliss I. (2004). Immunomodulating effects of whey proteins and their enzymatic digests. Int Dairy J, 14, 175-183. (Pubitemid 38203932)
197. Migliore-Samour D, Jollès P. 1988). Casein a prohormone with an immunomodulating role for the newborn? Experientia, 44, 188-193 (Pubitemid 18066616)
198. Migliore-Samour D, Floc'h F, Jollès P. (1989). Biologically active casein peptides implicated in immunomodulation. J Dairy Res, 56, 357-362.
199. Mikkelsen TL, Rasmussen E, Olsen A, Barkholt V, Froøkiaer H. (2006). Immunogenicity of ?-casein and glycomacropeptide. J Dairy Sci, 89, 824-830.
200. Mo R, Jin X, Li N, Ju C, Sun M, Zhang C, Ping Q. (2011). The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-Osulfate chitosan micelles. Biomaterials, 32, 4609-4620.
201. Mohanraj VJ, Barnes TJ, Prestidge CA. (2010). Silica nanoparticle coated liposomes: A new type of hybrid nanocapsule for proteins. Int J Pharm, 392, 285-293.
202. Mondon K, Zeisser-Labouèbe M, Gurny R, Möller M. (2011). Novel cyclosporin A formulations using MPEG-hexyl-substituted polylactide micelles: A suitability study. Eur J Pharm Biopharm, 77, 56-65.
203. Morel S, Ugazio E, Cavalli R, Gasco MR. (1996). Thymopentin in solid lipid nanoparticles. Int J Pharm, 132, 259-261. (Pubitemid 26158724)
204. Morris MC, Depollier J, Mery J, Heitz F, Divita G. (2001). A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol, 19, 1173-1176. (Pubitemid 33115705)
205. Mortensen MW, Björkdahl O, Soørensen PG, Hansen T, Jensen MR, Gundersen HJ, Bjoørnholm T. (2006). Functionalization and cellular uptake of boron carbide nanoparticles. The first step toward T cell-guided boron neutron capture therapy. Bioconjug Chem, 17, 284-290.
206. Mozafari MR. (2005). Liposomes: An overview of manufacturing techniques. Cell Mol Biol Lett, 10, 711-719. (Pubitemid 43161695)
207. Mrestani Y, Behbood L, Härtl A, Neubert RH. (2010). Microemulsion and mixed micelle for oral administration as new drug formulations for highly hydrophilic drugs. Eur J Pharm Biopharm, 74, 219-222.
208. Muchow M, Maincent P, Muller RH. (2008). Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm, 34, 1394-1405.
209. Mullally MM, Meisel H, FitzGerald RJ. (1996). Synthetic peptides corresponding to ?-lactalbumin and ?-lactoglobulin sequences with angiotensin-I-converting enzyme inhibitory activity. Biol Chem Hoppe-Seyler, 377, 259-260.
210. Muller RH, Maaen S, Weyhers H, Spechtb F, Lucks JS. (1996). Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int J Pharm, 138, 85-94. (Pubitemid 26241925)
211. Müller RH, Runge S, Ravelli V, Mehnert W, Thünemann AF, Souto EB. (2006). Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm, 317, 82-89. (Pubitemid 43866342)
212. Müller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery -a review of the state of the art. Eur J Pharm Biopharm, 50, 161-177. (Pubitemid 30326695)
213. Murakami S, Ono T, Sakai S, Ijima H, Kawakami K. (2006). Effect of diglucosamine on the entrapment of protein into liposomes. J Liposome Res, 16, 103-112. (Pubitemid 43861147)
214. Murthy N, Xu M, Schuck S, Kunisawa J, Shastri N, Fréchet JM. (2003). A macromolecular delivery vehicle for protein-based vaccines: Acid-degradable protein-loaded microgels. Proc Natl Acad Sci USA, 100, 4995-5000. (Pubitemid 36542647)
215. Musacchio T, Torchilin VP. (2011). Recent developments in lipid-based pharmaceutical nanocarriers. Front Biosci, 16, 1388-1412.
216. Muzykantov VR. (2001). Targeting of superoxide dismutase and catalase to vascular endothelium. J Control Release, 71, 1-21. (Pubitemid 32195437)
217. Myschik J, Lendemans DG, McBurney WT, Demana PH, Hook S, Rades T. (2006). On the preparation, microscopic investigation and application of ISCOMs. Micron, 37, 724-734. (Pubitemid 44189844)
218. Nagaoka S, Futamura Y, Miwa K, Awano T, Yamauchi K, Kanamaru Y, Tadashi K, Kuwata T. (2001). Identification of novel hypocholesterolemic peptides derived from bovine milk ?-lactoglobulin. Biochem Biophys Res Commun, 281, 11-17. (Pubitemid 32924392)
219. Nakamura Y, Yamamoto N, Sakai K, Okubo A, Yamazaki S, Takano T. (1995a). Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J Dairy Sci, 78, 777-783.
220. Nakamura Y, Yamamoto N, Sakai K, Takano T. (1995b). Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. J Dairy Sci, 78, 1253-1257.
221. Nanga RP, Brender JR, Xu J, Hartman K, Subramanian V, Ramamoorthy A. (2009). Three-dimensional structure and orientation of rat islet amyloid polypeptide protein in a membrane environment by solution NMR spectroscopy. J Am Chem Soc, 131, 8252-8261.
222. Nazzal S, Smalyukh II, Lavrentovich OD, Khan MA. (2002). Preparation and in vitro characterization of a eutectic based semisolid selfnanoemulsified drug delivery system (SNEDDS) of ubiquinone: Mechanism and progress of emulsion formation. Int J Pharm, 235, 247-265. (Pubitemid 34185455)
223. Nobs L, Buchegger F, Gurny R, Allémann E. (2004). Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci, 93, 1980-1992. (Pubitemid 39045480)
224. Ondetti MA, Cushman DW. (1984). Angiotensin-converting enzyme inhibitors: Biochemical properties and biological actions. CRC Crit Rev Biochem, 16, 381-411.
225. Ourique AF, Azoubel S, Ferreira CV, Silva CB, Marchiori MC, Pohlmann AR, Guterres SS, Beck RC. (2010). Lipid-core nanocapsules as a nanomedicine for parenteral administration of tretinoin: Development and in vitro antitumor activity on human myeloid leukaemia cells. J Biomed Nanotechnol, 6, 214-223.
226. Patton JN, Palmer AF. (2005). Photopolymerization of bovine hemoglobin entrapped nanoscale hydrogel particles within liposomal reactors for use as an artificial blood substitute. Biomacromolecules, 6, 414-424. (Pubitemid 40277041)
227. Paegelow I, Werner H. (1986). Immunomodulation by some oligopeptides. Methods Find Exp Clin Pharmacol, 8, 91-95. (Pubitemid 16127504)
228. Pardakhty A, Varshosaz J, Rouholamini A. (2007). In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int J Pharm, 328, 130-141. (Pubitemid 44895483)
229. Pardridge WM. (2007). shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev, 59, 141-152. (Pubitemid 46773051)
230. Park K, Kwon IC, Park K. (2011a). Oral protein delivery: Current status and future prospect. React. Funct. Polym, 71, 280-287.
231. Park S, Jeong U, Lee J, Park J. (2010). Preparation and Characterization of Bovine Serum Albumin-loaded Cationic Liposomes: Effect of Hydration Phase. J Pharm Inv, 40, 353-335.
232. Park SJ, Choi SG, Davaa E, Park JS. (2011b). Encapsulation enhancement and stabilization of insulin in cationic liposomes. Int J Pharm, 415, 267-272.
233. Parker F, Migliore-Samour D, Floc'h F, Zerial A, Werner GH, Jollès J, Casaretto M, Zahn H, Jollès P. (1984). Immunostimulating hexapeptide from human casein: Amino acid sequence, synthesis and biological properties. Eur J Biochem, 145, 677-682. (Pubitemid 15178138)
234. Patel HM, Ryman BE. (1976). Oral administration of insulin by encapsulation within liposomes. FEBS Lett, 62, 60-63.
235. Pedersen N, Hansen S, Heydenreich AV, Kristensen HG, Poulsen HS. (2006). Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands. Eur J Pharm Biopharm, 62, 155-162. (Pubitemid 43143267)
236. Peek LJ, Middaugh CR, Berkland C. (2008). Nanotechnology in vaccine delivery. Adv Drug Deliv Rev, 60, 915-928.
237. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. (2008). Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens. Int J Pharm, 364, 272-280.
238. Pihlanto LA, Antila P, Mäntsälä P, Hellman J. (1994). Opioid peptides produced by in vitro proteolysis of bovine caseins. Int Dairy J, 4, 281-301.
239. Pihlanto-Leppälä A, Paakkari I, Rinta-Koski M, Antila P. (1997). Bioactive peptide derived from in vitro proteolysis of bovine ?-lactoglobulin and its effect on smooth muscle. J Dairy Res, 64, 149-155. (Pubitemid 28117925)
240. Powell JS, Nugent DJ, Harrison JA, Soni A, Luk A, Stass H, Gorina E. (2008). Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost, 6, 277-283.
241. Prego C, Torres D, Fernandez-Megia E, Novoa-Carballal R, Quiñoà E, Alonso MJ. (2006a). Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree. J Control Release, 111, 299-308.
242. Prego C, Fabre M, Torres D, Alonso MJ. (2006b). Efficacy and mechanism of action of chitosan nanocapsules for oral peptide delivery. Pharm Res, 23, 549-556.
243. Pujals S, Fernàndez-Carneado J, López-Iglesias C, Kogan MJ, Giralt E. (2006). Mechanistic aspects of CPP-mediated intracellular drug delivery: Relevance of CPP self-assembly. Biochim Biophys Acta, 1758, 264-279. (Pubitemid 44282975)
244. Rachna R, Sneh A, Veena K. (2009). Polymerosomes of PCL and PEG Demonstrate Enhanced Therapeutic Efficacy of Insulin. Curr Nanosci, 5, 409-416.
245. Rawat M, Singh D, Saraf S, Saraf S. (2008). Lipid carriers: A versatile delivery vehicle for proteins and peptides. Yakugaku Zasshi, 128, 269-280. (Pubitemid 351237899)
246. Recio I, Visser S. (1999). Two ion-exchange chromatographic methods for the isolation of antibacterial peptides from lactoferrin. In situ enzymatic hydrolysis on an ion-exchange membrane. J Chromatogr A, 831, 191-201. (Pubitemid 29073705)
247. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. (2006). Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine, 2, 53-65. (Pubitemid 43964837)
248. Reis CP, Ribeiro AJ, Houng S, Veiga F, Neufeld RJ. (2007). Nanoparticulate delivery system for insulin: Design, characterization and in vitro/in vivo bioactivity. Eur J Pharm Sci, 30, 392-397. (Pubitemid 46442785)
249. Reis CP, Ribeiro AJ, Veiga F, Neufeld RJ, Damgé C. (2008). Polyelectrolyte biomaterial interactions provide nanoparticulate carrier for oral insulin delivery. Drug Deliv, 15, 127-139. (Pubitemid 351302237)
250. Rezzani R, Rodella LF, Fraschini F, Gasco MR, Demartini G, Musicanti C, Reiter RJ. (2009). Melatonin delivery in solid lipid nanoparticles: Prevention of cyclosporine A induced cardiac damage. J Pineal Res, 46, 255-261.
251. Rohloff CM, Shimek JW, Dungan SR. (2003). Effect of added ?-lactalbumin protein on the phase behavior of AOT-brineisooctane systems. J Colloid Interface Sci, 261, 514-523. (Pubitemid 36535468)
252. Roseanu A, Florian PE, Moisei M, Sima LE, Evans RW, Trif M. (2010). Liposomalization of lactoferrin enhanced its anti-tumoral effects on melanoma cells. Biometals, 23, 485-492.
253. Roudot-Algaron F, LeBars D, Kerhoas L, Einhorn J, Gripon JC. (1994). Phosphopeptides from Comté cheese: Nature and origin. J Food Sci, 59, 544-547.
254. Ryhänen EL, Pihlanto-Leppälä A, Pahkala E. (2001). A new type of ripened; low-fat cheese with bioactive properties. Int Dairy J, 11, 441-447. (Pubitemid 32752183)
255. Sadee W. 1986). Protein drugs: A revolution in therapy? Pharm Res 3, 3-6 (Pubitemid 17191134)
256. Saito T, Nakamura T, Kitazawa H, Kawai Y, Itoh T. (2000). Isolation and structural analysis of antihypertensive peptides that exist naturally in Gouda cheese. J Dairy Sci, 83, 1434-1440.
257. Sato M, Hosokawa T, Yamaguchi T, Nakano T, Muramoto K, Kahara T, Funayama K, Kobayashi A, Nakano T. (2002). Angiotensin I-converting enzyme inhibitory peptides derived from wakame (Undaria pinnatifida) and their antihypertensive effect in spontaneously hypertensive rats. J Agric Food Chem, 50, 6245-6252. (Pubitemid 35155365)
258. Sato R, Noguchi T, Naito H. (1986). Casein phosphopeptide (CPP) enhances calcium absorption from the ligated segment of rat small intestine. J Nutr Sci Vitaminol, 32, 67-76.
259. Sawant RR, Sawant RM, Kale AA, Torchilin VP. (2008). The architecture of ligand attachment to nanocarriers controls their specific interaction with target cells. J Drug Target, 16, 596-600.
260. Sawant RM, Hurley JP, Salmaso S, Kale A, Tolcheva E, Levchenko TS, Torchilin VP. (2006). "SMART" drug delivery systems: Doubletargeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem, 17, 943-949. (Pubitemid 44162612)
261. Schievano E, Calisti T, Menegazzo I, Battistutta R, Peggion E, Mammi S, Palù G, Loregian A. (2004). pH-Dependent conformational changes and topology of a herpesvirus translocating peptide in a membrane-mimetic environment. Biochemistry, 43, 9343-9351. (Pubitemid 38955467)
262. Schubert MA, Müller-Goymann CC. (2005). Characterisation of surfacemodified solid lipid nanoparticles (SLN): Influence of lecithin and nonionic emulsifier. Eur J Pharm Biopharm, 61, 77-86. (Pubitemid 41096691)
263. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. (1999). In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science, 285, 1569-1572. (Pubitemid 29420581)
264. Schwarze SR, Dowdy SF. (2000). In vivo protein transduction: Intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci, 21, 45-48. (Pubitemid 30100337)
265. Sedgwick MA, Trujillo AM, Hendricks N, Levinger NE, Crans DC. (2011). Coexisting aggregates in mixed aerosol OT and cholesterol microemulsions. Langmuir, 27, 948-954.
266. Sethuraman VA, Bae YH. (2007). TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J Control Release, 118, 216-224. (Pubitemid 46350711)
267. Sethuraman VA, Lee MC, Bae YH. (2008). A biodegradable pH-sensitive micelle system for targeting acidic solid tumors. Pharm Res, 25, 657-666.
268. Sha X, Yan G, Wu Y, Li J, Fang X. (2005). Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. Eur J Pharm Sci, 24, 477-486. (Pubitemid 40387261)
269. Shaji J, Patole V. (2008). Protein and Peptide drug delivery: Oral approaches. Indian J Pharm Sci, 70, 269-277.
270. Shaji S, Jain V. (2010). Solid Lipis Nanoparticles: A novel carrier for chemotherapy. Int J Pharm Pharm Sci, 3, 817-822.
271. Sharma A, Sharma US. (1997). Liposomes in drug delivery: Progress and limitations. Int J Pharm, 154, 123-140. (Pubitemid 27351317)
272. Sharma G, Wilson K, van der Walle CF, Sattar N, Petrie JR, Ravi Kumar MN. (2010). Microemulsions for oral delivery of insulin: Design, development and evaluation in streptozotocin induced diabetic rats. Eur J Pharm Biopharm, 76, 159-169.
273. Shaoyong L, Zhao B, Wang, FH, Wang, M, Xie SY, Wang SL, Han C, Zhu LY, Zhou WZ. (2010). Yak interferon-α loaded solid lipid nanoparticles for controlled release. Res in Vet Sci, 88, 148-153.
274. Shiozaki K, Shiozaki M, Masuda J, Yamauchi, A, Ohwada, S, Nakano, T, Yamaguchi, T, Saito, T, Muramoto, Koji, Sato, M. (2010). Identification of oyster-derived hypotensive peptide acting as angiotensin-I-converting enzyme inhibitor. Fis Sci, 76, 865-872.
275. Silva SV, Malcata FX. (2005). Caseins as source of bioactive peptides. Int Dairy J, 15, 1-15. (Pubitemid 39527112)
276. Simone EA, Dziubla TD, Colon-Gonzalez F, Discher DE, Muzykantov VR. (2007). Effect of polymer amphiphilicity on loading of a therapeutic enzyme into protective filamentous and spherical polymer nanocarriers. Biomacromolecules, 8, 3914-3921.
277. Singh R, Singh S, Lillard JW Jr. (2008). Past, present, and future technologies for oral delivery of therapeutic proteins. J Pharm Sci, 97, 2497-2523.
278. Singh TK, Fox PF, Healy A. (1997). Isolation and identification of further peptides in the diafiltration retentate of the water-soluble fraction of Cheddar cheese. J Dairy Res, 64, 433-443. (Pubitemid 127510076)
279. Sinswat P, Tengamnuay P. (2003). Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: Comparison with hydroxypropyl-and dimethyl-α-cyclodextrins. Int J Pharm, 257, 15-22. (Pubitemid 36507028)
280. Smacchi E, Gobbetti M. (1998). Peptides from several Italian cheeses inhibitory to proteolytic enzymes of lactic acid bacteria, Pseudomonas fluorescens ATCC 948 and to the angiotensin I-converting enzyme. Enzyme Microbial Tech, 22, 687-694. (Pubitemid 28312624)
281. Smacchi E, Gobbetti M. (2000). Bioactive peptides in dairy products: Synthesis and interaction with proteolytic enzymes. Food Microb, 17, 129-141.
282. Solaro R. (2008). Targeted Delivery of Proteins by Nanosized Carriers. J Polym Sci Part A: Polym Chem, 46, 1-11.
283. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. (2001). Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release, 70, 1-20. (Pubitemid 32144788)
284. Sriamornsak P Thongborisute J, Takeuchi H (2009). Liposome-Based Mucoadhesive Formulations for Oral Delivery of Macromolecules. BernkopSchnurch Editor, 169-193.
285. Stark B, Andreae F, Mosgoeller W, Edetsberger M, Gaubitzer E, Koehler G, Prassl R. (2008). Liposomal vasoactive intestinal peptide for lung application: Protection from proteolytic degradation. Eur J Pharm Biopharm, 70, 153-164.
286. Stroh M, Zimmer JP, Duda DG, Levchenko TS, Cohen KS, Brown EB, Scadden DT, Torchilin VP, Bawendi MG, Fukumura D, Jain RK. (2005). Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med, 11, 678-682. (Pubitemid 40868310)
287. Sütas Y, Soppi E, Korhonen H, Syväoja EL, Saxelin M, Rokka T, Isolauri E. (1996). Suppression of lymphocyte proliferation in vitro by bovine caseins hydrolyzed with Lactobacillus casei GG-derived enzymes. J Allergy Clin Immunol, 98, 216-224. (Pubitemid 26289405)
288. Taguchi Kazuaki, Maruyama Toru, Otagiri Masaki. (2011). Pharmacokinetic properties of hemoglobin vesicles as a substitute for red blood cells. Drug Met Rev, 43, 362-373.
289. Takeuchi H, Sugihara H. (2010). [Absorption of calcitonin in oral and pulmonary administration with polymer-coated liposomes]. Yakugaku Zasshi, 130, 1135-1142.
290. Teiji O, Tetsuhiro K, Yoshitaka O, Yutaka F. (2005). Hemodilution with liposomeencapsulated low-oxygen-affinity hemoglobin does not attenuate hypothermic cerebral ischemia in rats. J Artif Org, 8, 263-269.
291. Ten RM, Anderson PM, Zein NN, Temesgen Z, Clawson ML, Weiss W. (2002). Interleukin-2 liposomes for primary immune deficiency using the aerosol route. Int Immunopharmacol, 2, 333-344. (Pubitemid 34075422)
292. Teschemacher H, Koch G, Brantl V. (1997). Milk protein-derived opioid receptor ligands. Biopolymers, 43, 99-117. (Pubitemid 27291389)
293. Thirawong N, Thongborisute J, Takeuchi H, Sriamornsak P. (2008). Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes. J Control Release, 125, 236-245.
294. Thompson CJ, Tetley L, Cheng WP. (2010). The influence of polymer architecture on the protective effect of novel comb shaped amphiphilic poly (allylamine) against in vitro enzymatic degradation of insulin-towards oral insulin delivery. Int J Pharm, 383, 216-227.
295. Thongborisute J, Tsuruta A, Kawabata Y, Takeuchi H. (2006). The effect of particle structure of chitosan-coated liposomes and type of chitosan on oral delivery of calcitonin. J Drug Target, 14, 147-154. (Pubitemid 43878823)
296. Tiwari, Shailja, Goyal, Amit K, Khatri, Kapil, Mishra, Neeraj, Vyas, Suresh P. (2009). Gel core liposomes: An advanced carrier for improved vaccine delivery. J Microencaps, 26, 75-82.
297. Tokle T, McClements DJ. (2011). Physicochemical properties of lactoferrin stabilized oil-in-water emulsions: Effects of pH, salt and heating. Food Hydrocoll, 25, 976-982.
298. Torchilin VP. (2000). Drug targeting. Eur J Pharm Sci, 11 Suppl 2, S81-S91.
299. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. (2001). TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci USA, 98, 8786-8791. (Pubitemid 32678105)
300. Torchilin VP. (2006a). Multifunctional nanocarriers. Adv Drug Deliv Rev, 58, 1532-1555. (Pubitemid 44822608)
301. Torchilin VP. (2006b). Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng, 8, 343-375. (Pubitemid 44314821)
302. Torchilin VP. (2004a). Micellar nanocarriers: Pharmaceutical perspectives. Pharm Res, 24, 1-16. (Pubitemid 44902565)
303. Torchilin VP. (2004b). Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci, 61, 2549-2559. (Pubitemid 39591627)
304. Torchilin VP. (2008a). Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers, 90, 604-610.
305. Torchilin VP. (2008b). Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev, 60, 548-558. (Pubitemid 351215572)
306. Trif M, Guillen C, Vaughan DM, Telfer JM, Brewer JM, Roseanu A, Brock JH. (2001). Liposomes as possible carriers for lactoferrin in the local treatment of inflammatory diseases. Exp Biol Med (Maywood), 226, 559-564. (Pubitemid 32524502)
307. Trif M, Roseanu A, Brock JH, Brewer JM. (2007). Designing lipid nanostructures for local delivery of biologically active macromolecules. J Liposome Res, 17, 237-248. (Pubitemid 350133587)
308. Trotta M, Cavalli R, Gallarate M, et al. (2006). Microencapsulation of insulin into lipid carriers. Proc 5th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology.
309. Tsai IY, Tomczyk N, Eckmann JI, Composto RJ, Eckmann DM. (2011). Human plasma protein adsorption onto dextranized surfaces: A two-dimensional electrophoresis and mass spectrometry study. Colloids Surf B Biointerfaces, 84, 241-252.
310. Tsai J, Lin T, Chen J, Pan B. (2006). The inhibitory effects of freshwater clam (Corbicula fluminea, Muller) muscle protein hydrolysates on angiotensin I converting enzyme. Proc Biochem, 41, 2276-2281. (Pubitemid 44486078)
311. Türker S, Onur E, Ozer Y. (2004). Nasal route and drug delivery systems. Pharm World Sci, 26, 137-142. (Pubitemid 39012580)
312. Uchegbu IF. (1999). Parenteral drug delivery: 1. Pharm J, 263, 309-318. (Pubitemid 29414609)
313. Ugazio E, Cavalli R, Gasco MR. (2002). Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int J Pharm, 241, 341-344. (Pubitemid 34718035)
314. Ulrich AS. (2002). Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep, 22, 129-150. (Pubitemid 35222729)
315. van den Hoven JM, Van Tomme SR, Metselaar JM, Nuijen B, Beijnen JH, Storm G. (2011). Liposomal drug formulations in the treatment of rheumatoid arthritis. Mol Pharm, 8, 1002-1015.
316. Vega-Villa KR, Takemoto JK, Yàñez JA, Remsberg CM, Forrest ML, Davies NM. (2008). Clinical toxicities of nanocarrier systems. Adv Drug Deliv Rev, 60, 929-938.
317. Velluto D, Demurtas D, Hubbell JA. (2008). PEG-b-PPS diblock copolymer aggregates for hydrophobic drug solubilization and release: Cyclosporin A as an example. Mol Pharm, 5, 632-642.
318. Venkata S, Rao R, Shao J. (2008). Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs I. Formulation development. Int JPharm, 362, 2-9.
319. Vermeirssen V, Van Camp J, Verstraete W. (2004). Bioavailability of angiotensin I converting enzyme inhibitory peptides. Br J Nutr, 92, 357-366. (Pubitemid 40277058)
320. Wang Q, Hong G, Johnson GR, Pachter R, Cheung MS. (2010). Biophysical properties of membrane-active peptides based on micelle modeling: A case study of cell-penetrating and antimicrobial peptides. J Phys Chem B, 114, 13726-13735.
321. Wang RX, Tian ZG, Chen LY. (2011). Nano-encapsulations liberated from barley protein microparticles for oral delivery of bioactive compounds. Int J Pharm, 406, 1-2.
322. Wang SL, Xie SY, Zhu LY, Wang FH, Zhou WZ. (2009). Effects of poly (lactic-co-glycolic acid) as a co-emulsifier on the preparation and hypoglycaemic activity of insulin-loaded solid lipid nanoparticles. IET Nanobiotechnol, 3, 103-108.
323. Weiner LM. (1999). Monoclonal antibody therapy of cancer. Semin Oncol, 26, 43-51. (Pubitemid 29523410)
324. Werle M, Takeuchi H. (2009). Chitosan-aprotinin coated liposomes for oral peptide delivery: Development, characterisation and in vivo evaluation. Int J Pharm, 370, 26-32.
325. Werle M, Makhlof A, Takeuchi H. (2010). Carbopol-lectin conjugate coated liposomes for oral peptide delivery. Chem Pharm Bull, 58, 432-434.
326. Xi J, Guo R. (2007). Interactions between flavonoids and hemoglobin in lecithin liposomes. Int J Biol Macromol, 40, 305-311. (Pubitemid 46240288)
327. Xie S, Wang S, Zhao B, Han C, Wang M, Zhou W. (2008). Effect of PLGA as a polymeric emulsifier on preparation of hydrophilic proteinloaded solid lipid nanoparticles. Colloids Surf B Biointerfaces, 67, 199-204.
328. Xing L, Dawei C, Liping X, Rongqing Z. (2003). Oral colon-specific drug delivery for bee venom peptide: Development of a coated calcium alginate gel beads-entrapped liposome. J Control Release, 93, 293-300. (Pubitemid 37485951)
329. Xiong XB, Mahmud A, Uludag H, Lavasanifar A. (2007). Conjugation of arginine-glycine-aspartic acid peptides to poly (ethylene oxide)-b-poly (epsilon-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells. Biomacromolecules, 8, 874-884. (Pubitemid 46488467)
330. Xiong XY, Gong YC, Li ZL, Li YP, Guo L. (2011). Active targeting behaviors of biotinylated pluronic/poly (lactic acid) nanoparticles in vitro through three-step biotin-avidin interaction. J Biomater Sci Polym Ed, 22, 1607-1619.
331. Xu YY, Lu CT, Fu HX, Zhao YZ, Yang W, Li X, Zhang L, Li XK, Zhang M. (2011). Comparing the enhancement efficiency between liposomes and microbubbles for insulin pulmonary absorption. Diabetes Technol Ther, 13, 759-765.
332. Yao DG, Sun KX, Mu HJ, Zhou FM, Chen HH, Liu LJ, Liang N. (2009). [Preparation of cyclosporine A loaded mPEG-PLGA copolymer micelles and study its pharmacokinetics in rats]. Yao Xue Xue Bao, 44, 1410-1415.
333. Yang B, Wang JW,Tang B, Liu Y, Guo C, Yang P, Yu T, Li R, Zhao J, Zhang L, Dai Y, Li N. (2011). Characterization of Bioactive Recombinant Human Lysozyme Expressed in Milk of Cloned Transgenic Cattle. Plos One, 6, 1-10.
334. Yarosh DB. (2001). Liposomes in investigative dermatology. Photodermatol Photoimmunol Photomed, 17, 203-212. (Pubitemid 32834284)
335. Yoshikawa M, Tani F, Yoshimura T, Chiba, H. (1986). Opioid peptides from milk proteins. Agric Biol Chem, 50, 2419-2421. (Pubitemid 17189403)
336. Yoshioka T, Hashida M, Muranishi S, Sezaki H. (1981). Specific delivery of mitomycin C to the liver, spleen and lung: Nano-and microspherical carriers of gelatin. Int J Pharmacol, 81, 131-141. (Pubitemid 11078174)
337. Yuan X, Harada A, Yamasaki Y, Kataoka K. (2005). Stabilization of lysozyme-incorporated polyion complex micelles by the omegaend derivatization of poly (ethylene glycol)-poly (?,?-aspartic acid) block copolymers with hydrophobic groups. Langmuir, 21, 2668-2674. (Pubitemid 40448925)
338. Zanetti M. (2004). Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol, 75, 39-48. (Pubitemid 38166778)
339. Zhang N, Ping QN, Huang GH, Xu WF. (2005). Investigation of lectinmodified insulin liposomes as carriers for oral administration. Int J Pharm, 294, 247-259. (Pubitemid 40462339)
340. Zhang W, Ren FZ, Ge SY, Zhang LD, Jiang L, Mao XY, Guo HY. (2011). [Interaction of lactoferrin and its peptides with DPPC and DPPG liposomes studied by Raman spectroscopy]. Guang Pu Xue Yu Guang Pu Fen Xi, 31, 1533-1536.
341. Zhang Y, Li X, Zhou Y, Fan Y, Wang X, Huang Y, Liu Y. (2010a). Cyclosporin A-loaded poly (ethylene glycol)-b-poly (d,l-lactic acid) micelles: Preparation, in vitro and in vivo characterization and transport mechanism across the intestinal barrier. Mol Pharm, 7, 1169-1182.
342. Zhang Y, Li X, Zhou Y, Wang X, Fan Y, Huang Y, Liu Y. (2010b). Preparation and evaluation of poly (ethylene glycol)-poly (lactide) micelles as nanocarriers for oral delivery of cyclosporine a. Nanoscale Res Lett, 5, 917-925.
343. Zhu L, Ma J, Jia N, Zhao Y, Shen H. (2009). Chitosan-coated magnetic nanoparticles as carriers of 5-fluorouracil: Preparation, characterization and cytotoxicity studies. Colloids Surf B Biointerfaces, 68, 1-6.